Results 131 to 140 of about 77,746 (246)

Engineered Small Extracellular Vesicles Targeting Tumor‐Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment

Advanced Science, EarlyView.
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu, Feiyang Xu, Zhiming Zheng, Xiaodan Yang, Fang Yang, Pei Liu, Yuankun Chen, Yunshu Yang, Junli Zhao, Peiyan Yang, Xiaojing Zheng, Xiaohong Sun, Ping Mao, Qinwen Mao, Hao Guan, Haibin Xia, Weifeng Zhang, Dan Xiao   +17 more
wiley   +1 more source

A multicentre, prospective, randomized, open-label pragmatic trial to compare the effectiveness and safety of interferon beta-1a and glatiramer-acetate in paediatric patients affected by Multiple Sclerosis. [PDF]

Neurol Sci
Simone M, Palumbi R, Achille M, Micella S, Pascali M, Peschechera A, Gabellone A, Marzulli L, De Giacomo A, Maggi G, Reggiardo G, Felisi M, Padula R, Bonifazi D, Valeriani M, Papetti L, Lanzillo R, Clerici VT, Margari L.   +18 more
europepmc   +1 more source

A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva^® PSP. [PDF]

Front Psychol, 2022
Barello S, Paolicelli D, Bergamaschi R, Cottone S, D'Amico A, Annibali V, Paolillo A, Bosio C, Panetta V, Graffigna G.   +9 more
europepmc   +1 more source

Context‐Dependent Role of GDF15: GDF15+ Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Advanced Science, EarlyView.
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu   +9 more
wiley   +1 more source

Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD. [PDF]

Respir Res
Monk PD, Brookes JL, Tear VJ, Batten TN, Newall C, Mankowski M, Crooks MG, Singh D, Chaudhuri R, Leaker B, Lunn K, Reynolds S, Dudley S, Gabbay FJ, Holgate ST, Djukanovic R, Wilkinson TM.   +16 more
europepmc   +1 more source

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database. [PDF]

Front Neurol, 2021
Allignol A, Boutmy E, Sabidó Espin M, Marhardt K, Vermersch P.   +4 more
europepmc   +1 more source

Genetic Diagnosis and Discovery Enabled by Large Language Models

Advanced Science, EarlyView.
We demonstrate that large language models (LLMs) can facilitate genetic diagnosis and discovery. LLMs were used to solve four types of genetic problems of sequentially increased complexity. An LLM‐based pipeline could analyze genetic variants in the genomic sequences of human hearing loss or rare genetic disease patients and assist in identifying ...
Tao Tu, Khaled Saab, Weida Liu, Zhouqing Fang, Zhuanfen Cheng, Svetolik Spasic, Maja Djurisic, Hiroaki Mohri, Wenlong Ren, Anil Palepu, Juraj Gottweis, Alan Karthikesalingam, Kavita Kulkarni, Annalisa Pawlosky, Devon Bonner, Elijah Kravets, Shruti Marwaha, Hector R. Mendez, Matthew T. Wheeler, Jonathan A. Bernstein, Undiagnosed Diseases Network, Cheng‐Yu Tsai, Chen‐Chi Wu, Konstantina M. Stankovic, Vivek Natarajan, Gary Peltz   +25 more
wiley   +1 more source

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons. [PDF]

J Comp Eff Res
Jiang T, Shanmugasundaram M, Božin I, Freedman MS, Lewin JB, Shen C, Ziemssen T, Arnold DL.   +7 more
europepmc   +1 more source

Interferon beta-1a for COVID-19: critical importance of the administration route. [PDF]

Crit Care, 2020
Jalkanen J, Hollmén M, Jalkanen S.
europepmc   +1 more source

Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland. [PDF]

Pharmacoeconomics, 2021
Schur N, Gudala K, Vudumula U, Vadapalle S, Bhadhuri A, Casanova A, Adlard N, Schwenkglenks M.   +7 more
europepmc   +1 more source